Alan Sachs is the head of global research and development at Life Technologies. Previously, he was vice president of RNA Therapeutics for Merck Research Laboratories. He assumed leadership of Sirna Therapeutics in San Francisco and established the global RNA Therapeutics Department for Merck Research Laboratories effective January 4, 2007. Prior to this, Dr. Sachs assumed responsibility for the scientific leadership at Rosetta Inpharmatics LLC effective July 2002, responsibility for the Rosetta site effective March, 2004, and overall responsibility for the Department of Molecular Profiling in 2006. Dr. Sachs joined Merck & Co., Inc. as Director of Clinical Genomics for MRL in July 2001.
Prior to joining Merck, Dr. Sachs was Associate Professor of Molecular and Cell Biology while at the University of California at Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute in Cambridge. Dr. Sachs is one of the leading figures in the field of mRNA translation and regulation, and has made landmark contributions, particularly to the understanding of the role of the poly(A) tail in translation and mRNA stability.
Dr. Sachs graduated from Cornell University with a B.A. in Biochemistry; received his Ph.D. in Cell Biology at Stanford University; his M.D. from Stanford Medical School; and completed a post-doctoral fellowship in the Department of Biochemistry, Stanford University.
Where should any financial technology startup live? We’re here to urge you to look no further, and seriously consider Boston. Boston is and will remain the perfect home for FinTech startups today and for years to come. Read on to learn why we’re so confident.